Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “With almost half of the world’s hepatocellular carcinoma cases diagnosed in China, this approval marks a major advance for Chinese patients.”“In China, primary liver cancer ranks as the fourth most common malignancy and is the second leading cause of cancer death. With most patients diagnosed at the intermediate and advanced stages where surgery or other locoregional therapies are not an option, there is an urgent need for effective tr eatments for unresectable HCC”, said Prof. Shukui Qin, Leading Principal Investigator of the IMbrave150 study in China and Chairman of the Liver Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO). “The IM...
Most of the literature and the instructional information publications regarding facial plastic surgery procedures has historically been from North American or European sources. Because of that history, much of the focus and development of clinical surgical information and facial plastic procedures has been described utilizing a Caucasian patient base. However, there has been tremendous growth and expansion internationally in the interest in facial plastic procedures, and accordingly, the ethnic patient population base has greatly expanded.
Dalton Trans., 2021, Advance Article DOI: 10.1039/D1DT01460A, PaperLiping Qiao, Jiangping Liu, Shi Kuang, Xinxing Liao, Junfeng Kou, Liangnian Ji, Hui Chao A mitochondria-targetedBODIPY-Ir(III) conjugate acted as a photoinduced ROS generator and exerted high oxidative lethality towards triple-negative breast cancer cells at an ultralow concentration under irradiation. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
But rates higher for infection - related cancers, such as liver and stomach cancers, and cervical cancer
Progression - free survival longer with T - DXd versus T - DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane
Findings seen for screening - detected breast cancer, but not interval cancer risk
[WHO] I was greatly heartened by the global show of support demonstrated at the Global COVID-19 Summit hosted by the President of the United States of America, Joe Biden, on Wednesday, 22 September 2021.
Methamphetamine use in adults aged 18 to 64 years increased 43% between 2015 and 2019, astudy in JAMA Psychiatry has found. The study also found that overdose deaths involving psychostimulants other than cocaine, mostly methamphetamine, increased 180% during the same period.Beth Han, M.D., Ph.D., M.P.H., of the National Institute on Drug Abuse (NIDA) and colleagues examined data from 195,711 people who responded to the annual National Survey on Drug Use and Health (NSDUH) between 2015 and 2019. The NSDUH, published by the Substance Abuse and Mental Health Services Administration, is a comprehensive survey of approximately ...
Skewed drug metabolism of 6-mercaptopurine (6-MP) can jeopardize antileukemic effects and result in toxicities during the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. Allopurinol can alter 6-MP metabolism to maximize therapeutic effects while reducing toxicities. Over 75% of our patients with acute lymphoblastic leukemia or lymphoblastic lymphoma experienced a 6-MP-related toxicity. Review of metabolite date a showed 6-methylmercaptopurine nucleotide levels were>10,000 in 55% of the cohort, suggesting 6-MP shunting. Allopurinol was initiated in 12 of 23 shunters with resolution of toxicities. We...
Conclusion: Fever due to HDAC is relatively common but appears to frequently lack association with bacteremia during the time of HDAC administration. Broad-spectrum empiric antibiotic regimens including vancomycin may be unnecessary for these patients, particularly before they become neutropenic.
More News: Alcoholism | Allergy & Immunology | Avastin | Biotechnology | Bleeding | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | China Health | Cirrhosis | Diabetes | Endocrinology | Epidemiology | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Gastroenterology | Head and Neck Cancer | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Immunotherapy | Infectious Diseases | International Medicine & Public Health | Internet | Japan Health | Learning | Liver | Liver Cancer | Liver Disease | Lung Cancer | Men | OBGYN | Opthalmology | Oral Cancer | Partnerships | Pharmaceuticals | Science | Skin | Small Cell Lung Cancer | Statistics | Study | Switzerland Health | Toxicology | Universities & Medical Training | Urology & Nephrology | USA Health | WHO